Adalimumab Biosimilar Market By Indication (Rheumatoid Arthritis, Crohn’s Disease, Plaque Psoriasis, Ulcerative Colitis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Uveitis, Other Approved Indications); By Distribution Channel (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

What Is the Current Adalimumab Biosimilar Market Size and How Is the Treatment Landscape Evolving?

The Global Adalimumab Biosimilar Market was valued at USD 9.15 billion in 2025 and is projected to reach USD 16.62 billion by 2032, expanding at a CAGR of 8.9% during 2026–2032, according to Strategic Market Research.

 

Adalimumab biosimilars are highly similar versions of the reference biologic Humira used across chronic immune-mediated diseases in rheumatology, gastroenterology, dermatology, and ophthalmology. Their demand is increasingly tied to conversion of established Humira patients, biologic initiation among new patients, formulary preference, specialty-pharmacy access, reimbursement, public procurement, and the ability of manufacturers to offer patient-friendly formulations and delivery devices.

 

The market has shifted from an approval-driven phase into an access and volume-conversion phase. Ten adalimumab biosimilars entered the U.S. beginning in 2023, while several international markets accumulated years of switching experience before U.S. competition began. A 2025 global review identified 29 adalimumab products, including the originator, and found meaningful differences in concentration, citrate content, injection devices, dosage options, room-temperature shelf life, and patient-support programs despite comparable clinical performance.

 

Key Adalimumab Biosimilar Market Insights Across Major Segments

By Indication

• Rheumatoid Arthritis — Led with 28.0% in 2025. It causes joint pain, swelling, and stiffness. Biosimilars help control the disease at a lower cost.

• Crohn’s Disease — Held 18.0% and is growing at 9.7% CAGR. Biosimilars support long-term treatment and help reduce inflammation.

• Plaque Psoriasis — Accounted for 13.0%. Biosimilars are used mainly by stable patients, although newer biologics compete in new treatments.

• Ulcerative Colitis — Represented 11.0% and is growing at 10.0% CAGR. Biosimilars provide affordable long-term control of colon inflammation.

• Psoriatic Arthritis — Held 9.0%. Biosimilars help manage joint inflammation and psoriasis-related symptoms.

• Ankylosing Spondylitis — Accounted for 7.0%. Biosimilars offer a lower-cost option for long-term TNF-inhibitor treatment.

• Juvenile Idiopathic Arthritis — Represented 4.0%. Pediatric dosing, easy-to-use devices, and caregiver support are important.

• Hidradenitis Suppurativa — Held 4.0% and has the fastest growth at 10.7% CAGR. Increasing diagnosis and biologic use are driving demand.

• Uveitis — Accounted for 3.0% and is growing at 10.2% CAGR. Biosimilars help control eye inflammation and reduce steroid use.

• Other Approved Indications — Represented 3.0% and include other immune-related diseases treated with adalimumab.

 

By Distribution Channel

• Specialty Pharmacies — Led with 42.0%. They manage insurance approval, cold-chain delivery, refills, and patient support.

• Hospital Pharmacies — Held 28.0%. They support specialist treatment, bulk purchasing, and formulary management.

• Retail Pharmacies — Accounted for 24.0%. They provide convenient refills and may substitute biosimilars where allowed.

• Online Pharmacies — Represented 6.0% and are growing fastest at 12.0% CAGR due to home delivery and digital refill services.

 

By Region

• North America — Led with 42.0%, supported by strong payer coverage and multiple biosimilars.

• Europe — Held 30.0%, with mature adoption driven by tenders and switching policies.

• Asia Pacific — Accounted for 20.0% and is growing fastest at 10.7% CAGR due to rising healthcare access and local manufacturing.

• Latin America — Represented 5.0%, with demand supported by public tenders and lower-cost treatment.

• Middle East & Africa — Held 3.0%, with growth depending on government programs, healthcare infrastructure, and distribution access.

 

Payer-Led Switching Is Becoming the Main U.S. Volume Driver

The U.S. market initially demonstrated that regulatory approval and steep list-price discounts do not automatically create biosimilar volume. Adalimumab biosimilars captured only about 2% of the U.S. market during 2023, and earlier analysis showed that Humira’s rebate position, payer contracts, and limited preferential formulary access restricted early conversion.

That pattern changed substantially as major pharmacy benefit managers and health plans altered formularies. Samsung Bioepis reported that adalimumab biosimilar penetration reached 60% as of February 2026, although the calculation began incorporating Quallent private-label sales and still excluded certain Cordavis private-label products. Humira represented about 40% of measured volume, while Hyrimoz, Simlandi, Yuflyma, Hadlima, Cyltezo, and Amjevita had established measurable shares.

Medicare coverage also broadened considerably. The U.S. Department of Health and Human Services Office of Inspector General reported that 96% of Medicare Part D prescription drug plans and 88% of Medicare Advantage prescription drug plans covered at least one of the ten available Humira biosimilars in 2025, compared with 65% and 52%, respectively, in 2024. However, 99% of formularies covering both Humira and biosimilars placed them on the same cost-sharing tier, demonstrating that coverage does not necessarily mean preferential biosimilar positioning.

This distinction is commercially important. Adalimumab is primarily managed through the pharmacy benefit, where manufacturer rebates, PBM economics, specialty-pharmacy relationships, formulary exclusions, and private-label strategies can outweigh simple differences in published list prices. Mercer had anticipated this dynamic before the major launch wave, noting that meaningful biosimilar conversion would depend on pricing, contracting, payer reimbursement policies, preferential access, and supply stability rather than approval alone.

Private-label arrangements have subsequently become a significant competitive mechanism. CVS/Cordavis, Express Scripts/Quallent, and OptumRx/Nuvaila have worked with selected manufacturers on private-label adalimumab products. Research published in 2025 found that private-label products had become responsible for a substantial portion of measured biosimilar use, illustrating how PBM-linked distribution structures can determine which molecule gains volume even when several clinically comparable alternatives are available.

 

Product Design Is Emerging as a Commercial Differentiator

As clinical similarity becomes an expected requirement rather than a competitive advantage, manufacturers are differentiating adalimumab biosimilars through formulation, concentration, injection device, pediatric strengths, shelf life, support services, and interchangeability.

High-concentration and citrate-free formulations have become particularly important. The reference Humira franchise migrated toward a lower-volume high-concentration presentation, creating pressure on biosimilar manufacturers to offer comparable formats. The global adalimumab review published in 2025 identified high concentration, citrate-free formulation, autoinjector availability, broader dosage ranges, longer room-temperature stability, and patient support as practical attributes influencing product selection.

SIMLANDI illustrates the commercial importance of formulation parity. FDA approved the Alvotech-developed and Teva-commercialized product in February 2024 as the first high-concentration, citrate-free Humira biosimilar with an interchangeable designation in the U.S. Teva and Alvotech stated that high-concentration products represented nearly 88% of U.S. adalimumab prescriptions at that time, making concentration an important market-access consideration rather than a minor technical distinction.

Celltrion has followed a similar strategy with YUFLYMA. In May 2025, FDA expanded interchangeability to additional YUFLYMA presentations, giving the high-concentration, citrate-free product interchangeable status across all its marketed U.S. dosage forms and strengths. FDA's current documentation includes interchangeable 20 mg, 40 mg, and 80 mg presentations across prefilled syringe and autoinjector configurations where applicable.

FDA's Purple Book also shows interchangeable presentations for Amjevita, Abrilada, Cyltezo, Hadlima, Hyrimoz, Simlandi, and Yuflyma. Interchangeability can facilitate pharmacy substitution subject to applicable state law, but its commercial value still depends on whether the product is actually preferred by the patient's health plan and available through the relevant pharmacy network.

 

Switching Evidence Is Supporting Adoption, but Patient Experience Still Affects Retention

International experience is increasingly reducing clinical uncertainty surrounding originator-to-biosimilar and biosimilar-to-biosimilar switching. A 2025 BioDrugs review of real-world evidence outside the U.S. found that available evidence generally supports maintenance of efficacy and safety following adalimumab switching across immune-mediated inflammatory diseases. Studies of biosimilar-to-biosimilar switching also generally reported comparable disease control, remission, adverse-event, and immunogenicity outcomes.

Commercial implementation nevertheless involves more than therapeutic comparability. Patient surveys reviewed in the same publication showed that trust in clinicians, advance information, injection-device training, and familiarity with support programs can materially affect acceptance. Dissatisfaction following switching has been associated with insufficient information, device differences, injection experience, and reductions in manufacturer-provided support services.

U.S. real-world data illustrate why treatment retention deserves attention. Truveta analyzed 66,720 eligible Humira users and found that 13.3% had evidence of switching to an adalimumab biosimilar by April 2025. Among 8,594 switchers with adequate follow-up, 13.2% subsequently had evidence of switching back to Humira. Switching accelerated sharply during early 2024, coinciding with major formulary changes, demonstrating that payer decisions can generate rapid conversion but do not eliminate patient-level persistence issues.

Patient-support infrastructure therefore remains commercially relevant even in a highly price-competitive category. A 2025 international comparison found that support programs varied significantly by country and could include injection training, nursing services, reminders, online portals, and patient hotlines. Manufacturers facing substantial price erosion must balance these services against narrower margins, making efficient support delivery another point of competitive differentiation.

 

Indication Mix Supports Recurring Demand but Creates Different Growth Profiles

Rheumatoid arthritis remained the largest indication, accounting for 28.0% of the market or USD 2.562 billion in 2025, and is projected to expand at a CAGR of 7.8% through 2032. Its importance reflects a large established biologic-treated population and extensive physician experience with adalimumab. Much of the biosimilar opportunity comes from replacement of reference adalimumab rather than expansion of the anti-TNF treatment category itself.

Crohn’s disease represented 18.0%, equivalent to USD 1.647 billion, and is projected to grow at 9.7%. Ulcerative colitis represented 11.0%, or USD 1.007 billion, with a projected CAGR of 10.0%. Both indications benefit from recurring maintenance treatment and growing payer willingness to use biosimilars, while physician confidence is supported by accumulated switching evidence from countries where adalimumab biosimilars have been used since 2018.

Plaque psoriasis accounted for 13.0% or USD 1.190 billion, while psoriatic arthritis represented 9.0% or USD 0.824 billion. Biosimilars can capture established adalimumab use in these indications, although competition from IL-17, IL-23, JAK, and other targeted therapies limits the assumption that lower adalimumab pricing will automatically translate into dominance among new biologic starts.

Hidradenitis suppurativa represents a smaller but faster-growing opportunity, accounting for 4.0% of the market and carrying a 10.7% CAGR. Uveitis represented 3.0% and carries a 10.2% CAGR. In smaller indications, product breadth becomes particularly important because pediatric labeling, strength availability, injection configuration, and insurer coverage determine whether an individual biosimilar can address the full reference-product population.

 

Regional Adoption Reflects Different Procurement and Reimbursement Models

North America generated 42.0% of market revenue, equivalent to USD 3.843 billion in 2025. The region is now moving from slow launch-era penetration toward aggressive formulary-led conversion. Pricing remains fragmented: Samsung Bioepis' 2026 analysis shows some U.S. adalimumab biosimilars with WAC discounts of approximately 85–86% versus Humira, while other manufacturers retain multiple price points to serve rebate-oriented and low-list-price channels.

Europe represented 30.0%, or USD 2.745 billion. Its competitive structure differs because adalimumab biosimilars have been commercially available since Humira exclusivity expired in Europe in 2018. National tenders, hospital procurement, prescribing policies, and longer experience with non-medical switching have produced a more mature biosimilar environment than the initial U.S. pharmacy-benefit model.

Asia Pacific held 20.0% and is projected to record the fastest regional CAGR of 10.7%. Regional opportunity reflects greater biologic access, domestic biosimilar manufacturing capabilities, and expanding commercialization across markets including India, China, South Korea, Japan, and Australia. However, regulatory standards, reimbursement and procurement differ substantially between countries, making the region a collection of distinct national markets rather than a single adoption pathway.

Latin America represented 5.0%, while the Middle East & Africa accounted for 3.0%. Expansion in these regions depends heavily on public-sector purchasing, hospital formularies, tender participation, local regulatory pathways, distributor partnerships, and the ability of biosimilars to improve affordability relative to originator biologics.

 

Competition Is Shifting From Biosimilarity to Access, Portfolio and Supply Strategy

The leading competitive set includes Amgen's Amjevita, Boehringer Ingelheim's Cyltezo, Samsung Bioepis/Organon's Hadlima, Sandoz's Hyrimoz, Celltrion's Yuflyma, Alvotech/Teva's Simlandi, Biocon Biologics' Hulio, Pfizer's Abrilada, Fresenius Kabi's Idacio, and Yusimry. FDA records confirm a broad U.S. portfolio of Humira biosimilars with a growing number of interchangeable presentations.

Competitive strategy increasingly extends beyond individual product characteristics. Biocon Biologics secured full and exclusive global rights to Hulio from Fujifilm Kyowa Kirin Biologics in December 2025, taking responsibility for manufacturing, commercialization, and further development. The transaction gives Biocon greater control over supply economics and global lifecycle management at a time when price competition is increasing.

For manufacturers, sustainable share through 2032 will depend on gaining preferred formulary status, supporting reliable supply, offering formulations that align with established Humira use, maintaining patient-support capabilities despite price erosion, and securing pharmacy or PBM distribution relationships. The rapid rise in U.S. biosimilar penetration during 2025–2026 demonstrates the scale of the conversion opportunity, but it also shows that market leadership can change quickly when formularies are redesigned.

The principal constraint is that adalimumab biosimilars compete for a pool increasingly divided between originator conversion and alternative mechanisms of action. Strong price competition can expand access to adalimumab, but rheumatology, dermatology, and gastroenterology treatment pathways continue to incorporate newer biologics and targeted therapies. As a result, market growth through 2032 will depend less on the number of additional Humira biosimilars and more on how effectively existing products convert prescriptions, retain switched patients, secure reimbursement, and compete for new biologic starts.

 

Adalimumab Biosimilar Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 9.15 Billion
Revenue Forecast in 2032	USD 16.62 Billion
Overall Growth Rate	CAGR of 8.9% (2026–2032)
Base Year	2025
Historical Data	2019–2024
Unit	USD Billion, CAGR (2026–2032)
Segmentation	By Indication, By Distribution Channel, By Geography
By Indication	Rheumatoid Arthritis, Crohn’s Disease, Plaque Psoriasis, Ulcerative Colitis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Uveitis, Other Approved Indications
By Distribution Channel	Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography	North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country Scope	United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, United Arab Emirates, South Africa
Market Drivers	Payer-led switching, broader formulary coverage, lower-cost access to biologic treatment, high-concentration and citrate-free formulations, interchangeable designations, private-label PBM arrangements, public tenders, and expanding biosimilar manufacturing capacity
Customization Option	Available upon request